AstraZeneca confirmed plans to invest $50 billion in the United States by 2030, focusing on manufacturing and research facilities expansion. The commitment includes a $4 billion new factory in Virginia and expansions in Massachusetts, Maryland, Indiana, and Texas. The move supports AstraZeneca’s goal of generating half of its projected $80 billion annual revenue from the US market by the end of the decade. CEO Pascal Soriot framed the investment as a response to national security concerns and a bid to strengthen domestic pharmaceutical production amid policy discussions about import tariffs on drugs.